epocrates logo
epocrates logo
epocrates logo
  • 0

Herbs & Supplements

epocrates logo

Sign in to access our clinical decision support tools

Sign in Create Account

Formulary
No Formulary Selected

close

 

Select a medication above to begin.

eleuthero root

eleuthero (Eleutherococcus senticosus)

Sections:

  • Entire Monograph
  • Reported Uses
  • Reported Doses
  • Cautions
  • Drug Interactions
  • Adverse Reactions
  • Synonyms
  • Other Info
  • Add to Interaction Check

Entire Monograph

Reported Uses

  • NOTE: see Herb & Supplement Effectiveness Rating Definitions table
  • athletic performance [Insufficient Evidence]
  • bipolar disorder [Insufficient Evidence]
  • cardiovascular disease prevention [Insufficient Evidence]
  • chronic fatigue syndrome [Insufficient Evidence]
  • cognitive function [Insufficient Evidence]
  • common cold [Insufficient Evidence]
  • COVID-19 [Insufficient Evidence]
  • diabetes mellitus, type 2 [Insufficient Evidence]
  • diabetic neuropathy [Insufficient Evidence]
  • dry eye disease [Insufficient Evidence]
  • familial Mediterranean fever (FMF) [Insufficient Evidence]
  • fibromyalgia [Insufficient Evidence]
  • genital herpes [Possibly Effective]
  • hangover [Insufficient Evidence]
  • influenza [Insufficient Evidence]
  • osteoarthritis [Insufficient Evidence]
  • osteoporosis [Insufficient Evidence]
  • pneumonia [Insufficient Evidence]
  • quality of life [Insufficient Evidence]
  • rheumatoid arthritis [Insufficient Evidence]
  • stress [Insufficient Evidence]
  • URI [Insufficient Evidence]

Reported Doses

Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies with variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely

Special Note

[formulation clarification]
Info: extracts generally standardized to 0.112-1.12% eleutheroside content

Effectiveness Ratings

[see Herb & Supplement Effectiveness Rating Definitions table]

athletic performance

[Insufficient Evidence]
Dose: 400 mg PO bid

bipolar disorder

[Insufficient Evidence]
Dose: 750 mg PO tid; Info: for patients 12-17 yo; used with lithium

cardiovascular disease prevention

[Insufficient Evidence]
Dose: 500 mg PO qd

chronic fatigue syndrome

[Insufficient Evidence]
Dose: 2 g PO qd

cognitive function

[Insufficient Evidence]
Dose: 203 mg PO qd; Alt: 325 mg PO bid

COVID-19

[Insufficient Evidence]
Dose: 78 mg PO bid

diabetes mellitus, type 2

[Insufficient Evidence]
Dose: 480 mg PO qd

diabetic neuropathy

[Insufficient Evidence]
Dose: 480 mg PO qd

dry eye disease

[Insufficient Evidence]
Dose: 50 mg PO qd

genital herpes

[Possibly Effective]
Dose: 400 mg PO qd

influenza

[Insufficient Evidence]
Dose: 20-30 mg PO tid

pneumonia

[Insufficient Evidence]
Dose: 20 mL PO bid; Info: standardized solution containing 24.4% eleuthero root extract

quality of life

[Insufficient Evidence]
Dose: 300 mg PO qd

URI

[Insufficient Evidence]
Dose: 30 mL (5 mg/mL extract) PO tid; Alt: 22.8 mg PO tid

Copyright © 2026. All Rights Reserved. Republication or redistribution, including by framing or similar means, is prohibited without the prior written consent of copyright holder.

Select a medication above to begin.

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information